Structure via PubChem · Public domain (PubChem)
efinaconazole
Sign in to saveAlso known as (2R,3R)-2-(2,4-Difluorophenyl)-3-(4-methylene-1-piperidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol, KP-103
Efinaconazole, sold under the brand name Jublia and Clenafin among others, is a triazole antifungal compound discovered by Kaken Pharmaceutical, indicated for the treatment of onychomycosis, a fungal infection of the nail. Since it has low binding affinity with keratin, the main component of nails, it has superior nail-penetrating properties. It is approved for use in the United States, Canada, Japan and certain European countries as a 10% topical solution.
In the Vinony graph
Within Vinony's link graph, efinaconazole is referenced by 100 other articles, and connects out to antifungal, CYP51A1 and nail.
It is catalogued under topics including Beta-Hydroxyamphetamines, ECHA InfoCard ID from Wikidata and Fluoroarenes.
Its subject is documented across 5 Wikipedia language editions.
Chemical data
- Formula
- C18H22F2N4O
- Molecular weight
- 348.4 g/mol
- IUPAC name
- (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2014
- Admin. routes
- topical
- Indications
- tinea, tinea unguium
via ChEMBL · EBI
Research
281 papers- Efinaconazole in Onychomycosis.American journal of clinical dermatology · 2022
- Efinaconazole.2006
- Efinaconazole and Tavaborole.Journal of pharmacy practice · 2017
- Efinaconazole 10% solution: a comprehensive review of its use in the treatment of onychomycosis.Expert opinion on pharmacotherapy · 2024
- Efinaconazole topical solution (10%) for the treatment of onychomycosis in adult and pediatric patients.Expert review of anti-infective therapy · 2022
via PubMed
Wikidata facts
- Subclass of
- azole
- Mass
- 348.176168
- Has use
- medication
Show 6 more facts
- chemical formula
- C₁₈H₂₂F₂N₄O
- canonical SMILES
- CC(C(CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3
- isomeric SMILES
- C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3
- World Health Organisation international non-proprietary name
- efinaconazole
- subject has role
- antifungal
- Commons category
- Efinaconazole
Sources (2)
via Wikidata · CC0
~3 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- Efficacy
- History
- Economics
- References
- External links
Efinaconazole, sold under the brand name Jublia and Clenafin among others, is a triazole antifungal compound discovered by Kaken Pharmaceutical, indicated for the treatment of onychomycosis, a fungal infection of the nail. Since it has low binding affinity with keratin, the main component of nails, it has superior nail-penetrating properties. It is approved for use in the United States, Canada, Japan and certain European countries as a 10% topical solution.
Efinaconazole acts as a 14α-demethylase inhibitor.
Excerpted from Wikipedia’s “efinaconazole” article, available under the CC BY-SA 4.0 licence.